In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2024

Annual Industry Ranking And Forecast

Macro Challenges Make Calls On Newly Resilient Medtechs

Health Care Transition Accelerates And Sustainability Compliance Is Demanding Attention

Executive Summary

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

You may also be interested in...



CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Launch Of Team-AB Offers United Voice For UK Approved Bodies

Forum officially unveiled on 19 February to represent growing band of organizations designated against the UKCA mark.

Prostate Screening: UK Industry Body Explores Role In Study, Points To Growing Diagnostics Remit

Early diagnosis information is central to disease detection and will reduce treatment costs overall, says Nishan Sunthares, who heads the Association of British HealthTech Industries’ work on diagnostic technologies including IVDs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel